Evidence map›Paper›PMID 39236081›Full record

ArticlePLoS neglected tropical diseases2024

Epigenetic Biomarkers and the Wnt/β-Catenin Pathway in Opisthorchis viverrini-associated Cholangiocarcinoma: A Scoping Review on Therapeutic Opportunities.

Alok Kafle, Sutas Suttiprapa, Mubarak Muhammad, Jan Clyden B Tenorio, Roshan Kumar Mahato, Norhidayu Sahimin, Shih Keng Loong

Abstract readScoping Review
In one paragraph

Article in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Editorial: Parasite-induced liver diseases, volume II.Frontiers in cellular and infection microbiology · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alok KafleDepartment of Tropical Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.ORCID 0000-0002-0048-5699
Sutas SuttiprapaDepartment of Tropical Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.ORCID 0000-0002-2323-2344
Mubarak MuhammadDepartment of Physiology and Graduate School, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Jan Clyden B TenorioDepartment of Tropical Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Roshan Kumar MahatoFaculty of Public Health, Khon Kaen University, Khon Kaen, Thailand.
Norhidayu SahiminTropical Infectious Diseases Research & Education Centre, Universiti Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0003-1457-2758
Shih Keng LoongTropical Infectious Diseases Research & Education Centre, Universiti Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0001-7511-860X

Funding

Ministry of Higher Education, Malaysia under Dana Langganan SUKUK Pakej Rangsangan Ekonomi Prihatin Rakyat MO002-2021
6 · The paper itself

Abstract

backgroundEpigenetic modifications, such as DNA methylation and histone modifications, are pivotal in regulating gene expression pathways related to inflammation and cancer. While there is substantial research on epigenetic markers in cholangiocarcinoma (CCA), Opisthorchis viverrini-induced cholangiocarcinoma (Ov-CCA) is overlooked as a neglected tropical disease (NTD) with limited representation in the literature. Considering the distinct etiological agent, pathogenic mechanisms, and pathological manifestations, epigenetic research plays a pivotal role in uncovering markers and potential targets related to the cancer-promoting and morbidity-inducing liver fluke parasite prevalent in the Great Mekong Subregion (GMS). Emerging studies highlight a predominant hypermethylation phenotype in Opisthorchis viverrini (O. viverrini) tumor tissues, underscoring the significance of abnormal DNA methylation and histone modifications in genes and their promoters as reliable targets for Ov-CCA. PRINCIPAL

findingsRelevant published literature was identified by searching major electronic databases using targeted search queries. This process retrieved a total of 81 peer-reviewed research articles deemed eligible for inclusion, as they partially or fully met the pre-defined selection criteria. These eligible articles underwent a qualitative synthesis and were included in the scoping review. Within these, 11 studies specifically explored Ov-CCA tissues to investigate potential epigenetic biomarkers and therapeutic targets. This subset of 11 articles provided a foundation for exploring the applications of epigenetics-based therapies and biomarkers for Ov-CCA. These articles delved into various epigenetic modifications, including DNA methylation and histone modifications, and examined genes with aberrant epigenetic changes linked to deregulated signalling pathways in Ov-CCA progression.

conclusionsThis review identified epigenetic changes and Wnt/β-catenin pathway deregulation as key drivers in Ov-CCA pathogenesis. Promoter hypermethylation of specific genes suggests potential diagnostic biomarkers and dysregulation of Wnt/β-catenin-modulating genes contributes to pathway activation in Ov-CCA progression. Reversible epigenetic changes offer opportunities for dynamic disease monitoring and targeted interventions. Therefore, this study underscores the importance of these epigenetic modifications in Ov-CCA development, suggesting novel therapeutic targets within disrupted signalling networks. However, additional validation is crucial for translating these novel insights into clinically applicable strategies, enhancing personalised Ov-CCA management approaches.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaDNA MethylationEpigenesis, GeneticOpisthorchiasisOpisthorchisWnt Signaling PathwayAnimalsBiomarkers, TumorHumansBiomarkers, Tumor

Identifiers

PMID39236081
PMCPMC11407677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.